Recently developed genetically engineered mouse models have played a pivotal role in advancing our understanding of metabolic diseases, particularly in insulin resistance and obesity. These mouse models, specifically designed to mimic human metabolic dysfunctions, have provided a deeper insight into the molecular underpinnings of these conditions and have opened up new avenues for therapeutic interventions.

‍

TET2-Deficient Mouse Models: Linking Clonal Hematopoiesis to Liver Disease

One significant breakthrough comes from the use of TET2-deficient mouse models to explore the relationship between clonal hematopoiesis and chronic liver disease progression, particularly in the context of obesity and insulin resistance. Mice engineered to lack the TET2 gene in hematopoietic cells exhibited more severe liver inflammation and fibrosis when fed a high-fat diet, mirroring conditions such as non-alcoholic steatohepatitis (NASH) in humans. This genetic modification highlighted how the absence of TET2 leads to an enhanced inflammatory response in liver macrophages, contributing to chronic liver damage and fibrosis.

‍

Gdf15-Null Mice: Understanding Appetite and Energy Expenditure

Another crucial genetically engineered model involves Gdf15-null mice, which have been key in studying the metabolic effects of Growth Differentiation Factor 15 (GDF15). These mice, which lack the GDF15 gene, were shown to exhibit increased food intake and adiposity when subjected to a high-fat diet, providing evidence of GDF15’s role in regulating energy balance. Conversely, wild-type mice treated with recombinant GDF15 demonstrated enhanced energy expenditure and weight loss, even during caloric restriction. These models have provided a deeper understanding of how GDF15 signaling through the GFRAL receptor influences both appetite suppression and energy expenditure through pathways involving β-adrenergic signaling .

‍

Microbiome-Engineered Mouse Models: The Gut-Metabolism Connection

Further research utilized microbiome-engineered mouse models to assess the impact of gut microbial metabolism on insulin resistance. In these models, mice were engineered to harbor specific gut bacteria associated with insulin sensitivity or resistance. These studies revealed that the presence of insulin-sensitivity-associated bacteria improved host metabolic profiles, while insulin-resistance-associated microbes exacerbated the condition. This provided crucial insights into how microbial carbohydrate metabolism contributes to the development of metabolic syndrome.

‍

These genetically engineered mouse models, such as those lacking key genes like TET2 or GDF15, or those engineered to harbor specific microbiomes, continue to be instrumental in unraveling the complex mechanisms underlying metabolic diseases. By replicating human-like conditions, they offer a robust platform for testing new therapeutic strategies aimed at addressing the global burden of obesity, insulin resistance, and related metabolic disorders.

‍